FDA Adds Warning About Serious Risk of Heat-Related Complications with Antinausea Patch Transderm Scōp (Scopolamine Transdermal System)

Why It Matters

The added warning reshapes prescribing practices for a decades‑old anti‑nausea therapy, especially curbing off‑label pediatric use and prompting clinicians to monitor temperature control in vulnerable patients.

Key Takeaways

• FDA adds hyperthermia warning to Transderm Scōp labeling.
• 13 cases reported; 2 deaths, 4 hospitalizations.
• Risk highest in children ≤17 and adults ≥60.
• Symptoms appear within 72 hours of first patch use.
• Avoid external heat sources; remove patch if temperature rises.

Pulse Analysis

The scopolamine transdermal system, marketed as Transderm Scōp, has been a mainstay for motion‑sickness and postoperative nausea since its 1979 approval. Its anticholinergic action dampens the vestibular signals that trigger vomiting, delivering a steady dose over three days via a behind‑the‑ear patch. While effective, the drug also impairs sweating and thermoregulation, a side effect that becomes critical in hot environments or when patients use external heat sources such as heated blankets. This physiological interaction underpins the FDA’s new heat‑related risk warning.

FDA investigators identified 13 hyperthermia incidents linked to the patch through August 2024, including seven U.S. cases. Eight involved children 17 years or younger, four involved adults 60 years or older, and one involved a young adult. Four patients required hospitalization and two died, underscoring the severity of the reaction. Most events occurred within 72 hours of the initial application, often after exposure to warm conditions or misuse such as cutting the patch. The data also revealed concurrent anticholinergic symptoms—dry mouth, blurred vision, hallucinations—complicating diagnosis and highlighting the need for heightened vigilance, especially when the patch is used off‑label for pediatric drooling.

Clinicians now must incorporate temperature monitoring into patient counseling, emphasizing removal of the patch at the first sign of elevated body temperature or reduced sweating. The revised label also calls for explicit discussion of risks with older adults and caregivers of children, and for avoidance of external heat sources during therapy. Health‑care providers should reassess off‑label pediatric prescriptions, weighing the benefits against the newly quantified hyperthermia risk. Ongoing pharmacovigilance and prompt MedWatch reporting will be essential to refine safety guidelines and protect vulnerable populations as the industry adapts to this regulatory update.